Cellectis (France) Executives
| ALCLS Stock | EUR 2.35 0.03 1.26% |
Cellectis employs about 294 people. The company is managed by 25 executives with a total tenure of roughly 174 years, averaging almost 6.0 years of service per executive, having 11.76 employees per reported executive. Discussion of Cellectis' management performance can provide insight into the enterprise performance.
| Andre Choulika Chairman Chairman of the Board and CEO, Member of the Executive Committee |
| Stephane Depil President Senior Vice President - Research and Development and Chief Medical Officer |
Cellectis |
Cellectis Management Team Effectiveness
The company has return on total asset (ROA) of (0.2408) % which means that it has lost $0.2408 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.557) %, meaning that it generated substantial loss on money invested by shareholders. Cellectis' management efficiency ratios could be used to measure how well Cellectis manages its routine affairs as well as how well it operates its assets and liabilities.Cellectis Workforce Comparison
Cellectis is number one stock in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 609. Cellectis totals roughly 294 in number of employees claiming about 48% of equities under Health Care industry.
Cellectis Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Cellectis Price Series Summation is a cross summation of Cellectis price series and its benchmark/peer.
Cellectis Notable Stakeholders
A Cellectis stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Cellectis often face trade-offs trying to please all of them. Cellectis' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Cellectis' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Andre Choulika | Chairman of the Board and CEO, Member of the Executive Committee | Profile | |
| Stephane Depil | Senior Vice President - Research and Development and Chief Medical Officer | Profile | |
| Elsy Boglioli | Executive Vice President - Strategy and Corporate Development | Profile | |
| Mathieu Simon | Member of the Executive Committee, Senior Vice President | Profile | |
| Stefan Scherer | Senior Vice President Clinical Development and Deputy Chief Medical Officer | Profile | |
| William Monteith | Senior Vice President U.S. Manufacturing | Profile | |
| Thierry Moulin | CFO | Profile | |
| Eric Dutang | CFO, Member of the Executive Committee | Profile | |
| Laurent Arthaud | Director | Profile | |
| Pierre Bastid | Director | Profile | |
| Alain Godard | Advisor, Independent Director and Member of Compensation Committee | Profile | |
| Herve Hoppenot | Non-Executive Independent Director | Profile | |
| Annick Schwebig | Director | Profile | |
| David Sourdive | Co-Founder, Executive VP of Corporate Devel. and Director | Profile | |
| Rainer Boehm | Non-Executive Independent Director | Profile | |
| JeanMarie Messier | Independent Director | Profile | |
| Dr MBA | Chief Officer | Profile | |
| Valerie Cros | Principal Officer | Profile | |
| MarieBleuenn Terrier | General Counsel, Member of the Executive Committee | Profile | |
| Kyung NamWortman | Ex Officer | Profile | |
| Jean Epinat | Chief Officer | Profile | |
| Philippe Duchateau | Chief Scientific Officer | Profile | |
| Pascalyne Wilson | Director Communications | Profile | |
| Stephan Reynier | Chief Regulatory and Compliance Officer, Member of the Executive Committee | Profile | |
| MSc MSc | Chief Officer | Profile |
About Cellectis Management Performance
The success or failure of an entity such as Cellectis often depends on how effective the management is. Cellectis management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cellectis management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cellectis management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. Cellectis S.A. was founded in 1999 and is based in Paris, France. CELLECTIS operates under Pharmaceuticals And Biosciences classification in France and is traded on Paris Stock Exchange. It employs 161 people.
The data published in Cellectis' official financial statements usually reflect Cellectis' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Cellectis. For example, before you start analyzing numbers published by Cellectis accountants, it's critical to develop an understanding of what Cellectis' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Cellectis' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cellectis' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Cellectis' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cellectis. Please utilize our Beneish M Score to check the likelihood of Cellectis' management manipulating its earnings.
Cellectis Workforce Analysis
Traditionally, organizations such as Cellectis use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Cellectis within its industry.Cellectis Manpower Efficiency
Return on Cellectis Manpower
| Revenue Per Employee | 194.9K | |
| Revenue Per Executive | 2.3M | |
| Net Loss Per Employee | 388.4K | |
| Net Loss Per Executive | 4.6M | |
| Working Capital Per Employee | 812.9K | |
| Working Capital Per Executive | 9.6M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cellectis. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Complementary Tools for Cellectis Stock analysis
When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |